Health information to help you understand symptoms. It isn't a diagnosis.
Check symptoms

Research deep dives

Where heart failure treatment came from

Last reviewed November 17, 2026. OwieClear editorial team. Waiting for clinician review. Not medical advice. Talk with your doctor about your own care.

Heart failure treatment has reversed itself twice. A plant extract used for two centuries turned out to do far less than believed, and a class of drug everyone knew was dangerous turned out to be among the most effective.

The common thread is that bedside reasoning about a failing pump was wrong, and only randomised trials found it out.

Related pages: Heart failure

The bottom line

What we know
  • William Withering investigated foxglove for dropsy in the 1770s and published in 1785.
  • Digitalis dominated treatment for two centuries and was later shown not to improve survival.
  • The CONSENSUS trial in 1987 showed enalapril reduced mortality in severe heart failure.
  • Beta blockers were long considered contraindicated and are now a cornerstone.
  • Each advance came from blocking compensation rather than stimulating the heart.
What is still open
  • How much of the historical benefit of digitalis was real.
  • Why the beta blocker finding took so long to be accepted.

The story, step by step

  1. 1. Foxglove ()
  2. 2. Two centuries ()
  3. 3. CONSENSUS ()
  4. 4. The one everyone knew was wrong ()
What the evidence labels mean
GuidelineAn official recommendation from an expert group after weighing all the evidence.
Review of many studiesCombines the results of many studies (a systematic review or meta-analysis).
Randomized trialPeople were randomly given a treatment or a comparison, the best way to test cause and effect.
Large observational studyFollows many people over time. Shows strong links, but not always cause and effect.
Small or early studyA small study, case series, or first results. Needs to be confirmed.
Lab or animal studyDone in cells or animals. May not apply to people.
Part 1 of 4

Withering and the old woman's recipe

Small or early study

What happens

1775, Shropshire.

What the research shows

  • Dropsy, the old name for the massive fluid swelling of heart failure, was common and essentially untreatable.
  • William Withering, a physician and botanist, heard of a family remedy used by an old woman in Shropshire that sometimes relieved it.
  • He identified foxglove as the active ingredient among the herbs in the mixture and spent ten years testing preparations and doses on patients.
  • He published An Account of the Foxglove in 1785, documenting successes, failures and the toxic effects in detail.
  • His careful record of toxicity, including the visual disturbance and nausea of overdose, is why he is remembered as a careful clinical investigator rather than a herbalist.
  • Digitalis increases the force of contraction and slows conduction, which is why it helped both congestion and fast atrial fibrillation.

Why it matters

Withering's work is one of the earliest examples of systematic dose-finding, carried out on a plant remedy rather than against it.

What's still uncertain

  • How much of the observed benefit was from rate control in atrial fibrillation.

Read more

Next: Two centuries

Part 2 of 4

Stimulate the pump

Small or early study

What happens

The reasoning that seemed obvious.

What the research shows

  • For most of the next two hundred years, the logic was simple: a weak pump should be made to pump harder.
  • Digitalis remained the mainstay, alongside bed rest, salt restriction and, in severe cases, drawing fluid off through the skin with incisions.
  • Mercurial diuretics arrived in the 1920s, and modern loop diuretics in the 1960s, which transformed symptom relief.
  • Other drugs that stimulated contraction were developed, and several improved symptoms in the short term.
  • In trials, those stimulant drugs increased mortality. Driving a failing heart harder shortened life.
  • A large trial of digoxin in the 1990s found it reduced hospital admissions but did not improve survival.

Why it matters

The entire stimulate-the-pump era produced drugs that made people feel better and die sooner, which is the strongest argument in cardiology for measuring outcomes rather than symptoms alone.

What's still uncertain

  • Whether digoxin retains a role in modern practice.

Read more

Next: CONSENSUS

Part 3 of 4

The trial that changed the model

Small or early study

What happens

1987, and the opposite approach.

What the research shows

  • By the 1980s the neurohormonal model was emerging: the compensations were the problem, not the solution.
  • The CONSENSUS trial gave enalapril, an ACE inhibitor, to patients with severe heart failure and a very poor prognosis.
  • It was stopped early. Mortality was substantially reduced in the treatment group.
  • This was the first drug clearly shown to prolong life in heart failure, and it did so by blocking a compensation rather than stimulating the heart.
  • Further trials extended the finding to milder heart failure and to patients after a heart attack.
  • Spironolactone followed in 1999, and the ARNI in 2014, both continuing the same logic of blocking the hormonal cascade.

Why it matters

CONSENSUS changed the entire conceptual model of the disease, and every subsequent advance has followed from it.

What's still uncertain

  • How quickly practice actually changed after publication.

Read more

Next: The one everyone knew was wrong

Part 4 of 4

Beta blockers

Small or early study

What happens

Contraindicated, then a cornerstone.

What the research shows

  • Beta blockers reduce the force of contraction, so giving them to a failing heart was considered obviously dangerous and was formally contraindicated.
  • Scandinavian clinicians reported in the 1970s that some patients improved rather than deteriorated, and the reports were widely dismissed.
  • Trials through the 1990s, including studies of carvedilol, bisoprolol and metoprolol succinate, showed substantial reductions in mortality.
  • The explanation is that chronic adrenaline drive is toxic to heart muscle, and removing it allows reverse remodelling over months.
  • The practical lesson was that these drugs must be started low and increased slowly, because the early effect can be a temporary worsening.
  • SGLT2 inhibitors repeated the pattern in the 2010s: a diabetes drug whose cardiovascular safety trial unexpectedly showed a large reduction in heart failure hospitalisation.

Why it matters

Twice now, the drug that transformed heart failure treatment arrived from a direction nobody was looking, against prevailing reasoning.

What's still uncertain

  • Why acceptance of the beta blocker evidence took so long.

Read more

More plain-language reading

See something wrong or unclear on this page? Suggest a correction. OwieClear is for education only and isn't medical advice.